Coverage
Filings
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) |
| 26 Sept 2025 |
| 80,802 Orion Corporation A shares converted into B shares | 19 Sept 2025 |
| 337,000 Orion Corporation A shares converted into B shares | 20 Aug 2025 |
| Orion Corporation: Managers' transactions - Juhani Kankaanpää | 8 Aug 2025 |
| Orion Corporation: Managers' transactions - Satu Ahomäki | 4 Aug 2025 |